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Abstract 
Background: Hyperinsulinaemic hypoglycaemia (HH) is a group of clinically and genetically heterogeneous disor-
ders characterized by unregulated insulin secretion. Abnormalities in nine different genes (ABCC8, KCNJ11, GLUD1, GCK, 
HADH, SLC16A1, HNF4A, UCP2 and HNF1A) have been reported in HH, the most common being ABCC8 and KCNJ11. We 
describe the genetic aetiology and phenotype of Iranian patients with HH.
Methods: Retrospective clinical, biochemical and genetic information was collected on 23 patients with biochemi-
cally confirmed HH. Mutation analysis was carried out for the ATP-sensitive potassium (KATP) channel genes (ABCC8 
and KCNJ11), GLUD1, GCK, HADH and HNF4A.
Results: 78 % of the patients were identified to have a genetic cause for HH. 48 % of patients had mutation in HADH, 
whilst ABCC8/KCNJ11 mutations were identified in 30 % of patients. Among the diazoxide-responsive patients (18/23), 
mutations were identified in 72 %. These include two novel homozygous ABCC8 mutations. Of the five patients with 
diazoxide-unresponsive HH, three had homozygous ABCC8 mutation, one had heterozygous ABCC8 mutation inher-
ited from an unaffected father and one had homozygous KCNJ11 mutation. 52 % of children in our cohort were born 
to consanguineous parents. Patients with ABCC8/KCNJ11 mutations were noted to be significantly heavier than those 
with HADH mutation (p = 0.002). Our results revealed neurodevelopmental deficits in 30 % and epilepsy in 52 % of all 
patients.
Conclusions: To the best of our knowledge, this is the first study of its kind in Iran. We found disease-causing muta-
tions in 78 % of HH patients. The predominance of HADH mutation might be due to a high incidence of consan-
guineous marriage in this population. Further research involving a larger cohort of HH patients is required in Iranian 
population.
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Background
Hyperinsulinaemic hypoglycaemia (HH) is a group 
of clinically and genetically heterogeneous disorders 
characterized by dysregulation of insulin secretion by 
pancreatic β-cells [1]. Early diagnosis and treatment is 
important to prevent permanent brain damage [2]. HH 
can be either transient or persistent; transient forms of 
HH are usually secondary to conditions such as maternal 
diabetes mellitus or intra-uterine growth retardation [1]. 
The incidence of HH can vary from 1 in 35,000–40,000 in 
the general population [3] to 1 in 2,500 in some commu-
nities with high rates of consanguinity [4].
The clinical presentation can be varied ranging from 
completely asymptomatic, mild disease to severe dis-
ease unresponsive to medication needing surgical 
intervention [5]. The HH due to recessive mutations 
in ABCC8/KCNJ11 is usually severe and requires high 
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concentrations of intravenous glucose to maintain nor-
moglycaemia [5]. Hypoglycemic symptoms may vary 
from being non-specific (such as poor feeding, lethargy 
and irritability) to severe (such as apnea, seizures or 
coma). Macrosomia is a common feature in infants, but 
not all babies with HH are macrosomic [6]. There are 
two histological subtypes of CHI: diffuse and focal [7]. 
The diffuse form is inherited in an autosomal recessive 
(or dominant) manner whereas the focal form is sporadic 
in inheritance. The first line of medical therapy in HH 
includes diazoxide, which binds to the intact SUR1 com-
ponent of the KATP channels and prevents depolarization 
of the β-cell membrane and insulin secretion [1].
HH is caused by mutations in the key genes that are 
involved in regulation of insulin secretion from the pan-
creatic β-cells. So far, mutations in ABCC8, KCNJ11, 
GLUD1, GCK, HADH, SLC16A1, HNF4A, UCP2 and 
HNF1A have been identified to be involved in the patho-
genesis of HH [1, 8]. The most common causes of diffuse 
medically unresponsive HH are mutations in ABCC8 and 
KCNJ11. These two genes encode for the SUR1 (sulpho-
nylurea receptor 1 subunit) and Kir6.2 (inward-rectify-
ing potassium channel pore-forming subunit) proteins, 
respectively which constitute the KATP channel of the 
pancreatic β-cell membrane [2].
The inactivating mutations in ABCC8/KCNJ11 reduce 
or completely abolish the activity of the KATP channel, 
leading to unregulated insulin release despite severe 
hypoglycaemia [9]. The recessive inactivating mutations 
in ABCC8 and KCNJ11 usually cause severe HH, which 
is unresponsive to medical treatment with diazoxide. 
The molecular basis of recessive inactivating ABCC8 and 
KCNJ11 mutations involve defects in KATP channel bio-
genesis and turnover, channel trafficking from the ER and 
Golgi apparatus to the plasma membrane and alterations 
of channels in response to nucleotide regulation and 
open state frequency [10]. Dominant inactivating muta-
tions in ABCC8 and KCNJ11 usually cause HH with a 
milder phenotype [11].
Hyperinsulinism–hyperammonaemia syndrome (HI/
HA), the second most common form of HH is associ-
ated with activating missense mutations in GLUD1, 
which encodes the mitochondrial matrix enzyme, gluta-
mate dehydrogenase (GDH). Patients present with recur-
rent symptomatic postprandial hypoglycaemia following 
protein-rich meals (leucine-sensitive hypoglycaemia) as 
well as fasting hypoglycaemia accompanied by asympto-
matic elevations of plasma ammonia [12]. Mutations in 
HNF4A, HNF1A and GCK cause maturity-onset diabetes 
of the young (MODY) as well HH [8, 13].
Mutations in the mitochondrial HADH gene (encoding 
the enzyme L-3-hydroxyacyl-coenzyme A dehydroge-
nase, HADH), are a rare cause of HH [14]. This enzyme 
catalysis the conversion of L3-hydroxyacyl-CoAs of 
variable chain length to their corresponding 3-ketoacyl-
CoAs and exerts highest activity to 3-hydroxybutyryl-
CoA. HADH mutations can lead either to severe neonatal 
HH or to mild late onset HH [15]. All patients reported 
so far have responded to diazoxide and some had abnor-
mal acylcarnitine metabolites (raised plasma hydroxy-
butyrylcarnitine and urinary 3-hydroxyglutarate levels). 
Protein sensitivity has been demonstrated in patients 
with HADH mutations [16] and this has been confirmed 
in the HADH knockout mouse [17]. However the precise 
mechanism of dysregulated insulin secretion in patients 
with a HADH deficiency is not understood but might 
involve an interaction between GDH and HADH [17]. 
Genetic analysis for HADH gene is recommended in 
patients with diazoxide responsive HH from consanguin-
eous families, who are negative for mutations in the KATP 
channels [18].
Although clinical characteristics and genetic etiology 
of HH patients have been described in some studies [19–
21], little is known about HH in the Iranian population 
with a high rate of consanguineous marriages [22]. The 
aim of this study was to investigate genotype/phenotype 
correlations in a sample of Iranian patients with HH from 
Isfahan.
Methods
In this cross-sectional study, we collected data on the 
patients who visited the pediatric endocrinology out-
patient clinics and the infants who were referred to Al-
Zahra Hospital from September 1998 to July 2012. All 
infants and children were diagnosed with HH based on 
clinical and biochemical criteria [2]. Patients with a sec-
ondary cause of HH such as perinatal asphyxia, prema-
turity, intra-uterine growth restriction, and syndromic 
forms were excluded. The clinical data included age at 
presentation, birth weight, medications, neonatal history, 
epilepsy and neurological deficits, family history, history 
of hypoglycaemia following protein-rich meals and con-
sanguinity of parents. Serum ammonia level was checked 
in all patients.
Children were defined as being responsive to diazoxide 
when (a) feeding with normal frequency and volume (b) 
able to fast appropriately for age and maintain normal 
blood glucose levels (c) serum insulin level low or unde-
tectable at the end of the fast (d) appropriate increase in 
serum fatty acids and ketone bodies at the end of the fast 
[2]. Diazoxide-unresponsive patients either underwent 
near total pancreatectomy or were managed with combi-
nations of octreotide and diazoxide along with high calo-
rie feeds.
Written informed consent for genetic tests was 
obtained from parents of all patients. The study was 
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reviewed and approved by the Ethical Committee of Isfa-
han University of Medical Sciences.
Genomic DNA was extracted from peripheral leuko-
cytes using standard procedures. All exons and intron–
exon boundaries of ABCC8, KCNJ11, HADH, GLUD1, 
HNF4A and GCK genes were amplified by PCR. The 
products were sequenced using a BigDye Termina-
tor v3.1 Cycle sequencing Kit on an ABI 3730XL Ana-
lyzer (Applied Biosystems, Foster City, CA, USA) and 
sequences were compared with the reference sequence 
(NM_000525 for KCNJ11, NM_000352.3 for ABCC8, and 
NM_000162.3 for GCK) using Chromas (V.2.01, Techne-
lysium Pty Ltd, Tewantin QLD, Australia) or Mutation 
Surveyor software V3.24 (Softgenetics, State College, PA, 
USA). Mutation testing was done on parental samples 
when a mutation was identified in the child. If no muta-
tion was identified, testing for a partial/whole gene dele-
tion was undertaken using multiplex ligation-dependent 
probe amplification (MLPA).
Statistical analysis
Data are presented as mean  ±  standard deviation and 
frequency. The independent sample t test was used to 
assess continuous variables between two groups. The 
Mann–Whitney test was used for data that were not 
normally distributed. Analyses were performed using 
SPSS (IL, USA, version 19.0). Significant level was set as 
P < 0.05.
Results
Twenty-three patients with HH with age ranging from 
1  month to 21  years were included in this study. One 
patient with achondroplasia and three children with sec-
ondary HH due to intra-uterine growth restriction were 
excluded. The age at presentation ranged from neona-
tal period (day 1 of life) to 3 years. Eleven (47 %) of the 
patients were noted to be symptomatic within the first 
48 h after birth. The most common clinical symptom was 
seizure (82 %). All patients except two children were born 
at full term. The mean birth weight was 3,423 ±  757  g 
(with a range of 1,700–5,000 g). Only five patients (21 %) 
were macrosomic. Ten (43 %) of patients were female. 12 
(52  %) children with HH were born to consanguineous 
couples. Two families had two affected children.
A high frequency (30 %) of neurodevelopmental delay 
was observed in these patients. Furthermore, 12 (52  %) 
patients suffered from epilepsy. None of the patients had 
hyperammonemia.
A total number of 18 (78  %) patients responded to 
diazoxide. Five diazoxide-unresponsive patients under-
went near total pancreatectomy. One of them died at 
4  months of age due to thromboembolism in the post-
operative period. One other patient, who was managed 
with combinations of octreotide and diazoxide, died at 
3  months of age due to sepsis. Clinical characteristics 
and gene mutations of these patients were summarized 
in Table 1.
Disease causing mutations were identified in 78  % 
of the patients (48  % had HADH mutation, 26  % had 
ABCC8 and 4  % had KCNJ11 mutation) (Fig.  1). Of the 
five with diazoxide-unresponsive HH, three had homozy-
gous ABCC8 mutation, one had heterozygous ABCC8 
mutation, which was inherited from an unaffected 
father, and one had homozygous KCNJ11 mutation. All 
three diazoxide unresponsive patients with homozy-
gous ABCC8 mutation were managed by subtotal pan-
createctomy. One of these patients needed insulin due 
to hyperglycemia in the post-operative period. The other 
two patients were euglycemic on a small (5  mg/kg/day) 
dose of diazoxide. One patient with a paternally inherited 
mutation was treated non-surgically with octreotide and 
diazoxide. One patient with homozygous KCNJ11 muta-
tion was managed by total pancreatectomy.
Interestingly two patients with a novel homozygous 
intronic ABCC8 mutation were diazoxide responsive and 
HH resolved by 4 years of age in one of the two patients. 
The mechanism of this is not clear.
The same homozygous HADH mutation was identified 
in 11 children with diazoxide-responsive HH [frameshift 
mutation c.617delA, which is a deletion of an A nucleo-
tide at position 617 and is predicted to result in a pre-
mature termination at codon 219 (p.K206fsX14)]. This 
included two affected siblings in two different families. 
Eight (72 %) children with HADH mutation had a history 
of hypoglycemia following protein-rich meals, although 
no formal protein load test was done in these patients.
Infants with ABCC8/KCNJ11 mutations were heavier 
at birth in comparison to the patients with HADH muta-
tion (4,190 ±  550  g vs. 3,255 ±  318  g, P =  0.002). The 
mean age of presentation of patients with a HADH muta-
tion was 99.1 days in comparison to 1.14 days in patients 
with ABCC8 mutations; the difference was statistically 
significant (P = 0.004).
Discussion
In this study, 78 % of patients with HH from Isfahan, Iran 
were noted to have disease-causing mutations. It is very 
interesting to note that HADH mutation was the com-
monest genetic cause in this cohort (48  %) as opposed 
to the ABCC8 mutations, which was noted only in 26 % 
of patients. The higher incidence of patients with HADH 
mutation accounted for the higher rate of diazoxide 
responsiveness in this group (78 %). All diazoxide-unre-
sponsive patients in this series had identifiable mutations 
(ABCC8/KCNJ11), whilst no mutation was identified in 
28 % of diazoxide-responsive patients.
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In contrast to these observations, several other stud-
ies suggest a major role of KATP channel in the patho-
genesis of patients with HH [19, 21, 23]. In a large series 
of 417 patients with HH, mutations were identified in 
91  % of diazoxide-unresponsive probands, and in 47  % 
of diazoxide-responsive patients [20]. However, only 2 
cases (4 % of diazoxide-responsive probands) were posi-
tive for HADH mutation. In another large series involv-
ing 300 patients with HH [19], mutations were identified 
in 45.3  % of patients and ABCC8/KCNJ11 mutations 
were noted to be the commonest. Among the 22.4 % of 
patients who had mutations in the diazoxide responsive 
group, only 3 patients (1 % of all cases) had HADH muta-
tion [19].
In keeping with previous observation [14, 19, 20], all 
patients with HADH mutation in this group were diazox-
ide responsive, whilst the majority of patients (71 %) with 
ABCC8/KCNJ11 mutations were diazoxide-unrespon-
sive. As shown previously, patients with HADH mutation 
were diagnosed later and were of normal birth weight in 
comparison to ABCC8 mutations [19, 24].
The clinical presentation of patients with heterozy-
gous (autosomal dominant) ABCC8 mutations is vari-
able, ranging from mild medically responsive forms to 
severe early-onset HH and the vast majority of patients 
who do not respond to diazoxide have homozygous 
ABCC8 mutations [20]. We observed that three of the 
five patients with severe HH had homozygous ABCC8 
mutations. Interestingly a novel homozygous ABCC8 
mutation was identified in two patients with a mild form 
of HH that resolved completely. The precise mechanism 
of the course of HH in these patients is unclear.
Genetic analysis of HADH is generally suggested in 
patients with diazoxide responsive HH from consanguin-
eous families, who are negative for mutations in the KATP 
channels [18]. The Iranian population like some other 
populations, has a high level of consanguinity [22]. A 
higher rate of consanguineous marriages may favor the 
onset and increased frequency of autosomal recessive 
diseases in a population [22]. Parental consanguinity was 
observed in 45  % (5/11) of patients with HADH muta-
tion in our cohort. Hence the higher incidence of HADH 
mutation in our group of patients is very likely related 
to the higher rate of consanguineous marriages in these 
families. Also 80  % (4/5) of children with homozygous 
ABCC8 mutation had consanguineous parents.
Our results showed neurodevelopmental deficits in 
30  % of the patients and epilepsy in 52  % of all cases. 
The prevalence of mental retardation and epilepsy was 
reported to be 31 and 15  %, respectively in a group of 
patients with HH in Austria [25]. Long-term follow up 
of 114 patients with HH showed poor general outcome 
with a high degree of psychomotor or mental retardation 
(44 %) or epilepsy (25 %) [26]. Another study from Argen-
tina reported neurological impairment in 38  % of chil-
dren with HH [27], whereas a study from Greece which 
followed up 13 HH patients reported a good neurologi-
cal outcome without any psychomotor retardation [28]. 
It is well known that neonatal hypoglycemia is associated 
with neurodevelopmental complications [29–31].
Our study has several limitations. Firstly it includes a 
small number of patients from Isfahan, which may not be 
representative of the whole Iranian population. Secondly 
the data was collected on a retrospective basis from the 
Included
(n=23)
Diazoxide-
responsive
(n=18)
mutation
(n=13)
homozygous 
HADH (n=11)
Consanguineous
parents=5
Epilepsy=8
Neurodevelopmenta
l deicit =5
homozygous 
ABCC8(n=2)
Consanguineous 
parents=2
No epilepsy
No neurodevelopmental 
deicit
no mutation
(n=5)
Consanguineous
parents=2
Epilepsy=2
Neurodevelopmenta
l deicit =1
Diazoxide-
unresponsive
(n=5)
mutation
(n=5)
homozygous
ABCC8(n=3)
Consanguineous
parents=2
Epilepsy=2
Neurodevelopmental 
deicit =1
Heterozygous 
paternally 
inherited 
ABCC8 (n=1)
Non Consanguineous parents
Child died at 3 months of age
compound 
heterozgyous 
KCNJ11(n=1)
Consanguineous parents
Child died at 4 months of age
no mutation
(n=0)
Fig. 1 Summary of the genotype–phenotype correlation and long term outcome.
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medical records. Finally, an 18-F DOPA PET/CT scan 
was not available to differentiate focal from diffuse lesion.
Conclusion
This study first of its kind from Iran, demonstrates dis-
ease-causing mutations in 78  % of HH patients from 
Isfahan. Majority of these patients (78  %) responded to 
medical therapy with diazoxide. A high rate (48  %) of 
HADH mutation is seen in this population that might be 
attributed to a high rate of consanguineous marriages. 
Data shows a suboptimal long-term outcome with a high 
degree of neurodevelopmental deficits and epilepsy in 
these patients. Further research with a larger number of 
patients is necessary to identify the mechanism(s) of HH 
in Iranian population.
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